- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01439646
Study to Evaluate the Clinical Outcome in High Risk Patients Who Received Empirical Antifungal Therapy
Observational, Retrospective Study to Evaluate the Clinical Outcome in High Risk Patients Who Received Empirical Antifungal Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Objectives
Primary Objective:
- To study the effect of Empirical Antifungal therapy on clinical outcome in high risk patients with suspected Invasive Fungal Infection admitted in ICU/Critical care unit
Secondary Objectives:
- To know the current epidemiology of IFI and management approach in patients at high risk of Invasive fungal infections
- Identify the risk factors associated with Invasive fungal infections
To comment on the appropriateness of empirical therapy used based on proven/probable diagnosis
Inclusion criteria:
All Non-neutropenic patients admitted in the intensive care/critical care unit who are prescribed any form of pre-emptive / empirical Antifungal therapy during the specified study duration period
Exclusion criteria:
Neutropenic patients Patients with proven invasive fungal infections where antifungal therapy was initiated after the confirmation of Invasive fungal infection/Candidemia Patients who received prophylactic antifungal agents
Study Design
- Multi Center (Dual-center - Fortis Hospital and Apollo Hospital) Retrospective, Observational Study
- Study Patients: 100 in number
Retrospective data will be collected for all patients admitted in intensive care unit/Critical care unit (under the study investigators) who received any form of Empirical / Preemptive (not prophylactic) Antifungal therapy (of any duration, irrespective of culture positivity) as a suspected case of Invasive Fungal Infection.
Following details of patients will be captured
Demographics, primary and secondary diagnosis, co-morbidities, grade of infection, severity of sepsis and disease.
Daily hemodynamic parameters, routine blood tests including Total count and hematologic profile, renal profile, Liver function tests, electrolyte status, additional tests whatever was done as a course of the therapy.
Fungal C/S reports and any other sample culture reports
Duration of treatment, Changes in therapy, Adjuvant therapy - for relevant cases, Any Surgical procedures undertaken: e.g., surgical debridement, fasciotomy and dressing (as a part of the standard treatment according to available guidelines) - for relevant cases, Any additional invasive procedure (eg: Mechanical ventilation ), Reported adverse events
Recording of Risk factors for invasive fungal infections as detailed but not limited to:
- Diabetes,
- Use of immunosuppressants (Eg. steroids)
- Chronic Hemodialysis , TPN, Mechanical ventilation ,
- Sepsis/Septic shock, Multiorgan dysfunction (more than one organ),
- Non response to > 4 days of broad spectrum antibiotics,
- Structural lung disease,
- Major abdominal surgery,
Multifocal colonization
- Study Duration:
A period of one year starting backwards from December 2010 till January 2010.( max. 100 patients retrospectively tracking back from Dec 2010 whichever comes first ).
Statistical analysis
Appropriate statistical tools such as "Multiple logistic regressions" model will be used to analyze linkages between different parameters recorded in the study
Primary Endpoint:
- Mortality both Short term (while on antifungal therapy) and Long term (within 12 weeks of completion of antifungal therapy)
- Mean Duration of ICU (Intensive Care Unit) / HDU (High Dependency Unit stay after initiation of Antifungal Therapy
Secondary Endpoints:
The common pathogens associated with Invasive Fungal Infections
The common empirical antifungal agents used in suspected Invasive Fungal Infection
The mean time for initiation of Antifungal therapy after suspicion of invasive fungal infection.
The mean duration of antifungal therapy
The risk factors in patients with proven/probable invasive fungal infections
The appropriateness of antifungal agent based on microbiological and/or clinical outcome
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
West Bengal
-
Kolkata, West Bengal, India, 700107
- Raja dhar
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All Non-neutropenic patients (18-75yrs) admitted in the intensive care/critical care unit who are prescribed any form of pre-emptive / empirical Antifungal therapy during the specified study duration period
Exclusion Criteria:
- Neutropenic patients
- Patients with proven invasive fungal infections where antifungal therapy was initiated after the confirmation of Invasive fungal infection/Candidemia
- Patients who received prophylactic antifungal agents
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Non neutropenic, ICU, empiric ,antifungals
|
since it is an observational restrospective study hence no active intervention is planned
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mortality both Short term (while on antifungal therapy) and Long term (within 12 weeks of completion of antifungal therapy)
Time Frame: 6 months
|
6 months
|
Mean Duration of ICU (Intensive Care Unit) / HDU (High Dependency Unit stay after initiation of Antifungal Therapy
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The common pathogens associated with Invasive Fungal Infections
Time Frame: 6 months
|
6 months
|
The common empirical antifungal agents used in suspected Invasive Fungal Infection
Time Frame: 6 months
|
6 months
|
The mean time for initiation of Antifungal therapy after suspicion of invasive fungal infection
Time Frame: 6 months
|
6 months
|
The risk factors in patients with proven/probable invasive fungal infections
Time Frame: 6 months
|
6 months
|
The appropriateness of antifungal agent based on microbiological and/or clinical outcome
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: raja dhar, MD, Fortis Hospital, Kolkata
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- Rdhar India
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Antifungal Therapy
-
The University of QueenslandUnknownAntifungal AgentsBelgium, Spain, Finland, United States, Australia, Canada, France, Greece, Hong Kong, Italy, Malaysia, Netherlands, Portugal
-
Astellas Pharma S.A.S.CompletedUse of Micafungin (Mycamine®) as Antifungal Prophylaxis in Haematology and Onco-haematology (OLYMPE)Antifungal Prophylaxis | HaemopathyFrance
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedAntifungal AgentsItaly
-
Population CouncilCompleted
-
GlaxoSmithKlineCompleted
-
Assiut UniversityUnknownAntifungal Drugs in Onychomycosis
-
PfizerCompletedAntifungal Prophylaxis of Invasive Fungal InfectionsCanada, Spain, Greece, France, Portugal, United Kingdom, Czech Republic, Egypt, Jordan, Russian Federation, Switzerland, Turkey
-
University of SevilleCompletedGait | Physical Therapy | Sports Physical Therapy | Exercise TherapySpain
-
Biotronik SE & Co. KGCompletedCardiac Resynchronization Therapy | Pacemaker TherapyGermany, Austria, Spain, Switzerland
-
Rambam Health Care CampusUnknownPrevalence of Fungal Infection in Patients Undergoing Oral Cavity Surgery Without Treatment With Antifungal Drug
Clinical Trials on it is a retrospective study, hence no active intervention
-
Hospital Sirio-LibanesCompletedEpipericardial Fat NecrosisBrazil
-
QuantalX NeuroscienceCompletedHealthy | Hemorrhage | Cognitive Impairment | Dementia | Fibromyalgia | TBI (Traumatic Brain Injury) | Cognitive Decline | Concussion, Brain | MS (Multiple Sclerosis) | Adhd | CVA | ABD | MciIsrael
-
BERTHILLIER JulienCompletedNeurological Disorder
-
Zhejiang Cancer HospitalCompletedBreast Cancer | PI3K/AKT/mTOR Pathway Mutation | EverolimusChina
-
Children's Hospital of Fudan UniversityCompletedProlonged Mechanical VentilationChina
-
The University of Texas Health Science Center,...CompletedWound InfectionUnited States
-
Cairo UniversityCompleted
-
Oxford University Hospitals NHS TrustCompleted
-
Universitair Ziekenhuis BrusselRecruiting